Maksim Labkouski
- Edwards Life Sciences (NYSE:EW) announced it has completed the sale of its critical care business to Becton Dickinson (NYSE:BDX) for $4.2B in cash and expanded its stock buyback program.
- The medical device maker said its board has authorized an additional $1.5B for stock repurchases. Edwards recently entered into a $500M accelerated share repurchase agreement on top of $500M shares repurchased in August through a 10b5-1 agreement and open market repurchases.
- Edwards said that following the $1B repurchase, it has $1.4B remaining in its authorization, according to a statement.
